Xultophy® 100/3.6 is a combination of insulin degludec, a long-acting human insulin analog, and liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus inadequately controlled on basal insulin (less than 50 units daily) or liraglutide (less than or equal to 1.8 mg daily).
Filling Xultophy® 100/3.6 prescriptions
One starting dose for all patients1
Start patients converting from basal insulin or liraglutide at 16 units (16 units of insulin degludec and 0.58 mg liraglutide).1
- Therapy with basal insulin and liraglutide should be discontinued prior to initiation of Xultophy® 100/3.61
- Dose once daily at the same time each day with or without food1
Every 3-4 days based on FPG1
Patients should titrate their dosage up or down by 2 units every 3 to 4 days until the FPG target identified by their doctor is achieved.
- Maximum dose: 50 units=50 units of insulin degludec and 1.8 mg liraglutide1
- In clinical trials, patients adjusted their dose on Monday and Thursday of each week2
Dosing and titration resources
Download the dosing card for all dosing and titration information in 1 place.
Give each patient starting Xultophy® 100/3.6 take-home titration instructions by filling out this dosing worksheet.
Xultophy® 100/3.6 is Tresiba® (insulin degludec)
combined with Victoza® (liraglutide)1
Don’t forget to order NovoFine® Plus 32G pen needlesb
NovoFine® Plus: our shortest and thinnest needle available is ultra-strong and designed to resist bending or breaking.
Storage and handling1
No-wait injection: Patients do not need to wait to inject after removing the Xultophy® 100/3.6 Pen from the refrigerator.1
bNeedles are sold separately and may require a prescription in some states.